The offering removes near-term financing risk and funds the critical BLA submission for AMT-130, but the 7.8% dilution and 7.2% discount create immediate selling pressure. Watch for the BLA submission in Q3 2026 and any updates on confirmatory study alignment with FDA. The stock's recent run-up (+60% in prior week per historical data) suggests the offering may have been anticipated; the discount may trigger profit-taking in the near term.
QURE drugs
QURE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Jun 25 $49.10entry
- T+1 · 5mo ago −3.24%α −2.52% · $47.51
- T+5 · 5mo ago −8.00%α −9.56% · $45.17
- T+20 · 4mo ago −19.69%α −20.22% · $39.43
- T+60 · due 8w ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
uniQure priced a $225M underwritten public offering of 4,945,055 ordinary shares at $45.50/share, a ~7.2% discount to the prior close of $49.04. Net proceeds of ~$211M will fund commercialization readiness, a confirmatory study for lead gene therapy AMT-130 (Huntington's disease), and pipeline development. The offering comes days after the company announced FDA alignment to accept Phase I/II data as the primary basis for a BLA submission under accelerated approval, a major regulatory de-risking event. The 7.8% dilution (4.95M new shares vs 63.0M outstanding) is a near-term overhang, but the capital raise removes a key financing overhang and funds the path to a pivotal BLA filing in Q3 2026.
Key Facts
- Offering of 4,945,055 ordinary shares at $45.50/share, raising ~$225M gross / ~$211M net proceeds
- Underwriters have a 30-day option to purchase up to an additional 741,758 shares
- Public offering price represents a ~7.2% discount to the June 23, 2026 close of $49.04
- Post-offering shares outstanding: 67,978,304 (68,720,062 if underwriters exercise option in full), a ~7.8% increase from 63,033,249
- Net proceeds of ~$211M will fund AMT-130 commercialization readiness, confirmatory study, pipeline development, and general corporate purposes
- On June 17, 2026, uniQure announced FDA alignment to accept Phase I/II data as primary basis for BLA under accelerated approval, with submission planned for Q3 2026
- Immediate dilution of $41.72 per share for new investors (public offering price of $45.50 vs. as-adjusted net tangible book value of $3.78)
- Lock-up agreements restrict insider sales for 60 days post-offering
Financial Impact
~$211M net capital infusion (~$242.7M if greenshoe exercised), representing ~6.8% of pre-offering market cap of $3.1B. Dilution of ~7.8% to existing shareholders.
Risk Factors
- Dilution of ~7.8% from new shares, with potential for further dilution if underwriters exercise greenshoe
- BLA submission and accelerated approval for AMT-130 remain subject to FDA alignment on confirmatory study design and acceptance of Phase I/II data
- Pre-revenue biotech with no approved products; commercialization and pipeline execution risk
- PFIC status risk for U.S. holders could create adverse tax consequences
- Stock volatility expected given limited trading volume and binary regulatory catalysts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-077336 |
| Document: tm2618428d2_ex-filingfees.htm | 0001104659-26-077336 |
| Document: 0001104659-26-077336-index-headers.html | 0001104659-26-077336 |
| Document: 0001104659-26-077336-index.html | 0001104659-26-077336 |
| Document: 0001104659-26-077336.txt | 0001104659-26-077336 |
Track record
38 reports on QURE
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers